Jan 6 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals (N:VRX)
International Inc VRX.N VRX.TO appointed Howard Schiller its
interim chief executive, effective immediately.
Schiller has stepped in for Michael Pearson (L:PSON), who remains
hospitalized with a severe bout of pneumonia, Valeant said on
Wednesday.
Schiller was previously Valeant's chief financial officer
from December 2011 to June 2015 and he currently serves on the
company's board.